Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 18, 2019
Daily News
November 18, 2019
- Finance Officials, Payers Grow Jittery as Xolair’s Pollen Allergy Nod Looms
November 18, 2019
- MHLW Panel to Discuss Eisai’s Insomnia Med and More on Nov. 29, Skips Ono’s Cachexia Drug Again
November 18, 2019
- Shionogi Wins US Approval for Antibiotic Fetroja
November 18, 2019
- Inpatient Generic Use Tops 80% in Japan Hospitals: Chuikyo
November 18, 2019
- 8.2% of Hospitals Have Formularies: Chuikyo Survey
November 18, 2019
- MHLW Orders Label Revisions for Xtandi, Erleada to Include Interstitial Lung Disease to ADR List
November 18, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…